{
    "clinical_study": {
        "@rank": "97711", 
        "arm_group": {
            "arm_group_label": "Arsenic Trioxide", 
            "arm_group_type": "Experimental", 
            "description": "Patients receive arsenic trioxide IV over 1-4 hours on days 1-5 and 8-12. Treatment repeats every 28 days for a maximum of 6 courses in the absence of disease progression or unacceptable toxicity.\nPatients are followed every 2-3 months for 1 year and then annually thereafter."
        }, 
        "brief_summary": {
            "textblock": "RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing\n      so they stop growing or die.\n\n      PURPOSE: Phase II trial to study the effectiveness of arsenic trioxide in treating children\n      who have advanced neuroblastoma or other solid tumors."
        }, 
        "brief_title": "Arsenic Trioxide in Treating Patients With Advanced Neuroblastoma or Other Childhood Solid Tumors", 
        "completion_date": {
            "#text": "May 2009", 
            "@type": "Actual"
        }, 
        "condition": [
            "Brain and Central Nervous System Tumors", 
            "Childhood Germ Cell Tumor", 
            "Extragonadal Germ Cell Tumor", 
            "Kidney Cancer", 
            "Liver Cancer", 
            "Neuroblastoma", 
            "Ovarian Cancer", 
            "Retinoblastoma", 
            "Sarcoma"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma, Renal Cell", 
                "Kidney Neoplasms", 
                "Liver Neoplasms", 
                "Nervous System Neoplasms", 
                "Neuroblastoma", 
                "Ovarian Neoplasms", 
                "Retinoblastoma", 
                "Central Nervous System Neoplasms", 
                "Neoplasms, Germ Cell and Embryonal", 
                "Neuroectodermal Tumors, Primitive, Peripheral", 
                "Sarcoma"
            ]
        }, 
        "detailed_description": {
            "textblock": "OBJECTIVES:\n\n        -  Determine the response rates of patients with advanced neuroblastoma or other pediatric\n           solid tumors treated with arsenic trioxide.\n\n        -  Determine the toxicity of this drug in these patients.\n\n      OUTLINE: Patients are stratified according to type of disease (neuroblastoma with\n      progressive disease vs neuroblastoma with stable refractory disease vs other solid tumor).\n\n      Patients receive arsenic trioxide IV over 1-4 hours on days 1-5 and 8-12. Treatment repeats\n      every 28 days for a maximum of 6 courses in the absence of disease progression or\n      unacceptable toxicity.\n\n      Patients are followed every 2-3 months for 1 year and then annually thereafter."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "DISEASE CHARACTERISTICS:\n\n          -  Histologically confirmed neuroblastoma or other pediatric solid tumor (nonmyeloid and\n             nonlymphoid) including the following:\n\n               -  Ewing's family of tumors/primitive neuroectodermal tumor\n\n               -  Retinoblastoma\n\n               -  Nephroblastoma\n\n               -  Osteosarcoma\n\n               -  Rhabdomyosarcoma\n\n               -  Desmoplastic small round-cell tumor\n\n               -  Hepatoblastoma\n\n               -  Germ cell tumors\n\n               -  Medulloblastoma\n\n          -  Relapsed from or resistant to prior standard anticancer therapy and/or no known\n             standard therapy available\n\n          -  Measurable disease (e.g., solid mass with definable dimensions) OR\n\n          -  Evaluable disease (e.g., bone marrow involvement or malignant pleural effusion)\n\n        PATIENT CHARACTERISTICS:\n\n        Age:\n\n          -  40 and under\n\n        Performance status:\n\n          -  Not specified\n\n        Life expectancy:\n\n          -  Not specified\n\n        Hematopoietic:\n\n          -  Not specified\n\n        Hepatic:\n\n          -  Bilirubin no greater than 2.5 times upper limit of normal (ULN)\n\n        Renal:\n\n          -  Creatinine no greater than 2.5 times ULN\n\n        Cardiovascular:\n\n          -  Absolute QT interval no greater than 460 msec in the presence of adequate potassium\n             and magnesium levels\n\n        Other:\n\n          -  No pre-existing neurotoxicity/neuropathy grade 2 or greater\n\n          -  No pre-existing convulsive disorder\n\n          -  No active serious infections uncontrolled by antibiotics\n\n          -  Negative pregnancy test\n\n          -  Fertile patients must use effective contraception\n\n        PRIOR CONCURRENT THERAPY:\n\n        Biologic therapy:\n\n          -  Not specified\n\n        Chemotherapy:\n\n          -  More than 3 weeks since prior cytotoxic chemotherapy\n\n          -  No other concurrent cytotoxic chemotherapy\n\n        Endocrine therapy:\n\n          -  Not specified\n\n        Radiotherapy:\n\n          -  Concurrent radiotherapy allowed provided measurable or evaluable disease exists\n             outside radiation field\n\n        Surgery:\n\n          -  Not specified\n\n        Other:\n\n          -  No other concurrent investigational agents"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "40 Years", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "22", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "September 13, 2001", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00024258", 
            "org_study_id": "01-042", 
            "secondary_id": [
                "P30CA008748", 
                "MSKCC-01042", 
                "CTI-1059", 
                "NCI-G01-2014"
            ]
        }, 
        "intervention": {
            "arm_group_label": "Arsenic Trioxide", 
            "intervention_name": "arsenic trioxide", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Arsenic trioxide"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "metastatic osteosarcoma", 
            "recurrent childhood rhabdomyosarcoma", 
            "regional neuroblastoma", 
            "disseminated neuroblastoma", 
            "stage 4S neuroblastoma", 
            "recurrent neuroblastoma", 
            "stage III childhood liver cancer", 
            "stage IV childhood liver cancer", 
            "recurrent childhood liver cancer", 
            "childhood hepatoblastoma", 
            "stage III Wilms tumor", 
            "stage IV Wilms tumor", 
            "stage V Wilms tumor", 
            "recurrent Wilms tumor and other childhood kidney tumors", 
            "intraocular retinoblastoma", 
            "extraocular retinoblastoma", 
            "recurrent retinoblastoma", 
            "recurrent osteosarcoma", 
            "childhood germ cell tumor", 
            "metastatic childhood soft tissue sarcoma", 
            "recurrent childhood soft tissue sarcoma", 
            "localized unresectable neuroblastoma", 
            "previously untreated childhood rhabdomyosarcoma", 
            "childhood desmoplastic small round cell tumor", 
            "untreated childhood medulloblastoma", 
            "recurrent childhood medulloblastoma", 
            "previously treated childhood rhabdomyosarcoma", 
            "metastatic Ewing sarcoma/peripheral primitive neuroectodermal tumor", 
            "recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor", 
            "childhood teratoma", 
            "childhood malignant testicular germ cell tumor", 
            "childhood malignant ovarian germ cell tumor", 
            "childhood extragonadal germ cell tumor", 
            "recurrent childhood malignant germ cell tumor"
        ], 
        "lastchanged_date": "April 16, 2013", 
        "link": {
            "description": "Clinical trial summary from the National Cancer Institute's PDQ\u00ae database", 
            "url": "http://cancer.gov/clinicaltrials/MSKCC-01042"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "New York", 
                    "country": "United States", 
                    "state": "New York", 
                    "zip": "10021"
                }, 
                "name": "Memorial Sloan-Kettering Cancer Center"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase II Study of Arsenic Trioxide in Neuroblastoma and Other Pediatric Solid Tumors", 
        "overall_official": {
            "affiliation": "Memorial Sloan-Kettering Cancer Center", 
            "last_name": "Brian H. Kushner, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "May 2009", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Response rate after every 3 courses during treatment and then every 2-3 months for 1 year after completion of treatment", 
            "safety_issue": "No", 
            "time_frame": "1 year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00024258"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Toxicity after every course during treatment", 
            "safety_issue": "Yes", 
            "time_frame": "1 year"
        }, 
        "source": "Memorial Sloan-Kettering Cancer Center", 
        "sponsors": {
            "collaborator": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Memorial Sloan-Kettering Cancer Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2001", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2013"
    }, 
    "geocoordinates": {
        "Memorial Sloan-Kettering Cancer Center": "40.714 -74.006"
    }
}